Feb 5th 2019

Cancer growth in the body could originate from a single cell – targeting it could revolutionise treatment

 

Cancer remains a frightening and largely incurable disease. The toxic side effects of chemotherapy and radiation make the cure often seem as bad as the ailment, and there is also the threat of recurrence and tumour spread.

Cancer treatment still follows a practically medieval method of cut, burn or poison. If the growth can’t be cut out through surgery, it may be burnt away with radiation or poisoned by chemotherapy. As a result, cancer therapy remains a daunting diagnosis for patients and treatment options seem limited for a disease which causes one in six deaths globally.

The failure to innovate in cancer treatment may lie in the very poor success rate of clinical trials. Approximately 95%-98% of new anti-cancer drugs actually fail phase III clinical trials, the phase in which new treatments are compared with existing therapy options. This is a staggering statistic. No other business could possibly survive with such an abysmal success rate.

Most drugs are made to target “bulk” cancer cells, but not the root cause: the cancer stem cell. Cancer stem cells, also known as “tumour-initiating cells”, are the only cells in the tumour that can make a new tumour. New therapies that specifically target and eradicate these cancer stem cells are needed to prevent tumours growing and spreading, but for that there needs to be more clarity around the target.

Our new research may have discovered such a target. We have identified and isolated cells within different cancerous growths which we call the “cell of origin”. Our experiments on cancer cells derived from a human breast tumour found that stem cells – representing 0.2% of the cancer cell population – have special characteristics.


Read more: Drug-resistant cancers kill millions – here's how we're tackling them


They generate vast amounts of energy and proliferate rapidly. We believe that they resemble the cancer cell of origin that has escaped senescence – the natural process of cell ageing and “death” which concludes a healthy cell life cycle. These are thought to be the first cancer cells which start the process of uncontrolled cell multiplication and cause tumours to form.

These cancer stem cells undergo anchorage-independent growth, also known as growth in suspension, without any tissue attachment. This is how metastasis occurs – spreading via the blood vessels and lymphatic vessels. These features put them front and centre as a new target for anti-cancer therapy.

With astonishing luck, these energetic cancer stem cells are colour-coded which means they have a natural phosphorescent glow, making them easy to identify and target.

Now that we have found them and we know how they behave, it should be relatively simple to find drugs to target cancer stem cells. In our new paper we have already shown that they are easily targeted with a mitochondrial inhibitor or a cell cycle inhibitor such as Ribociclib, an FDA-approved drug in the US which would prevent their proliferation.

Ultimately, this means that if we focus on energetic cancer stem cells, we may be able to directly hit the target. We might be able to turn cancer into a manageable chronic disease, like diabetes. We believe that we have arrived at the start of a new, more fruitful, road in cancer therapy. As a consequence, “big pharma” drug screening should actually focus on cancer stem cells and their relevant targets.

 

Michael P. Lisanti, Professor of Translational Medicine, University of Salford

This article is republished from The Conversation under a Creative Commons license. Read the original article.

Browse articles by author

More Essays

Nov 16th 2013

This article was originally posted on Truthdig, www.truthdig.com, poste

Oct 21st 2013

Following on the heels of a new book by Jesse Ventura that maintains Lee Harvey Oswald was not John Kennedy’s lone assassin, plus a movie just out about the event, entitled “Parkland,” several books are about to be released to coincide with the 50th anniversary of

Sep 30th 2013

The demand for gossipy detail on writer J.D. Salinger’s private life seems to be a bottomless pit.

Sep 1st 2013

Alvin Lucier’s book: Music 109: Notes on Experimental Music, reviewed by Michael Johnson is in the Music Review section.

Aug 2nd 2013

I thought the book business was being choked to death by television and iPods but I must be wrong. Clean, well-lighted superstores are still going strong. Could customers merely be doing penance for spending too much time slumped on their living room couch? 

Jul 22nd 2013
Margaret Brown: You have your main character creating the story of his deceased wife’s affair through memory and invention. It’s a novel approach to narrative — how did you arrive at it?
Mary L.
Jul 20th 2013

The first time I encountered poet Dana Gioia was in 1991 when I read his controversial essay in The Atlantic Monthly, “Can Poetry Matter?” and then the book with that title that followed. Gioia has deeply influenced my own thinking about poetry, about literature and about work.

Jun 19th 2013
Journalists who left their native countries to report on the outside world find few things more distressing than the death throes of their profession. As today’s newspapers shrink, fold and “go digital”, television turns to entertainers and opinionators.
May 31st 2013

Robert Craft knew from an early age that his considerable musical gifts would never be quite enough to make him a great composer, conductor or performer.

May 20th 2013

Adventurous readers, myself included, make a practice of looking for talented new writers who are just waiting to be discovered. These solitary artists are often buried alive in the overcrowded publishing world, wondering if word-of-mouth will ever kick in.

May 20th 2013
None of us can say for certain how starvation might affect our behavior but I’m guessing that slow death by hunger is one of the most degrading ways to exit this life.